NCT05013424View on ClinicalTrials.gov

A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

July 7, 2022

Study Completion Date

July 7, 2022

Conditions
Glabellar Lines
Interventions
DRUG

Formulation A: OnabotulinumtoxinA

Intramuscular Injection

DRUG

Formulation B: OnabotulinumtoxinA

Intramuscular Injection

DRUG

Formulation C: OnabotulinumtoxinA

Intramuscular Injection

Trial Locations (5)

78660

Austin Institute for Clinical Research /ID# 227367, Pflugerville

85308

Advanced Research Associates - Glendale /ID# 227368, Glendale

33146-1837

Skin Research Institute LLC /ID# 227366, Coral Gables

70130-4353

Etre Cosmetic Dermatology and Laser Center /ID# 227365, New Orleans

10549-3028

The Center for Dermatology Cosmetics & Laser Surgery /ID# 227369, Mount Kisco

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY